ChemicalBook > CAS DataBase List > IPI-549

IPI-549

Product Name
IPI-549
CAS No.
1693758-51-8
Chemical Name
IPI-549
Synonyms
Eganelisib;IPI-549;CS-2414;IPI-549(IPI549);IPI549 (Eganelisib);Eganelisib (IPI-549);IPI-549; IPI 549; IPI549.;Eganelisib, 10 mM in DMSO;Eganelisib (IPI-549) ，S8330;IPI-549, 98%, a potent and selective PI3Kγ Inhibitor
CBNumber
CB13147769
Molecular Formula
C30H24N8O2
Formula Weight
528.56
MOL File
1693758-51-8.mol
More
Less

IPI-549 Property

Density 
1.37±0.1 g/cm3(Predicted)
storage temp. 
-20°C
solubility 
Soluble in DMSO (up to at least 25 mg/ml)
form 
solid
pka
10.81±0.46(Predicted)
color 
Pale yellow
Stability:
Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month.
InChIKey
XUMALORDVCFWKV-IBGZPJMESA-N
SMILES
C12=C(C(N[C@H](C3=CC4=C(C(=O)N3C3=CC=CC=C3)C(C#CC3=CN(C)N=C3)=CC=C4)C)=O)C(N)=NN1C=CC=N2
CAS DataBase Reference
1693758-51-8
More
Less

Safety

HS Code 
2933998090
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H302Harmful if swallowed

H315Causes skin irritation

H319Causes serious eye irritation

H335May cause respiratory irritation

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

More
Less

N-Bromosuccinimide Price

Cayman Chemical
Product number
26416
Product name
IPI-549
Packaging
5mg
Price
$120
Updated
2024/03/01
Cayman Chemical
Product number
26416
Product name
IPI-549
Packaging
25mg
Price
$384
Updated
2024/03/01
Cayman Chemical
Product number
26416
Product name
IPI-549
Packaging
1mg
Price
$36
Updated
2024/03/01
Cayman Chemical
Product number
26416
Product name
IPI-549
Packaging
10mg
Price
$223
Updated
2024/03/01
TRC
Product number
I739410
Product name
IPI549
Packaging
5mg
Price
$95
Updated
2021/12/16
More
Less

IPI-549 Chemical Properties,Usage,Production

Description

IPI-549 (1693758-51-8) is a potent and highly selective inhibitor of PI3K-γ in both biochemical (IC50= 16 nM) and cellular (IC50= 12.2 nM) assays.1Macrophage PI3K-γ has been found to be a critical switch between immune stimulation and suppression.2IPI-549 has been used to reshape tumor immune microenvironments and promote cytotoxic T-cell-mediated tumor regression. Resistance to immune checkpoint blockade in 4T1 and B16-GMCSF tumors was overcome when anti-PD-1 or anti-CTLA4 therapies were combined with PI3K-γ inhibition via IPI-549.3IPI-549 mono-treatment also resulted in tumor growth inhibition in several cancer cell lines.3IPI-549 has also been shown to modulate P-glycoprotein-mediated multidrug resistance.4

Uses

IPI-549 is a selective phosphoinositide-3-kinase (PI3Kγ) Inhibitor. PI3Kγ inhibitors can be used to develop potential treatment for inflammatory and autoimmune diseases.

in vivo

Eganelisib (IPI549) demonstrates favorable pharmacokinetic properties and robust inhibition of PI3K-γ mediated neutrophil migration. In vivo (mice, rats, dog, and monkeys), Eganelisib has excellent oral bioavailability, low clearance, and distributed into tissues with a mean volume of distribution of 1.2 L/kg. Overall, Eganelisib has a favorable pharmacokinetic profile to allow potent and selective inhibition of PI3K-γ in vivo. The t1/2 of IPI-549 for mouse, rat, dog and monkey is 3.2, 4.4, 6.7 and 4.3 h, respectively. Eganelisib significantly reduces neutrophil migration in a dose dependent manner in this model when administered orally at all of the tested doses[1].

IC 50

PI3Kγ: 16 nM (IC50); PI3Kα: 3.2 μM (IC50); PI3Kβ: 3.5 μM (IC50)

References

[1] CATHERINE A. EVANS*. Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate[J]. ACS Medicinal Chemistry Letters, 2016, 7 9: 862-867. DOI:10.1021/acsmedchemlett.6b00238
[2] MEGAN M. KANEDA. PI3Kγ is a molecular switch that controls immune suppression[J]. Nature, 2016, 539 7629: 437-442. DOI:10.1038/nature19834
[3] OLIVIER DE HENAU. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells[J]. Nature, 2016, 539 7629: 443-447. DOI:10.1038/nature20554
[4] ALBERT A. DE VERA . Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo[J]. Cancer letters, 2019, 442: Pages 91-103. DOI:10.1016/j.canlet.2018.10.020

IPI-549 Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

IPI-549 Suppliers

China 115 United States 11 Global 126
Shanghai YuanQi Biotechnology Co., Ltd.
Tel
+86-2332782371 +86-18120098618
Email
sales@adobechem.com
Country
China
ProdList
1250
Advantage
50
Twochem Co.Ltd.
Tel
021-58111628 15800915896
Fax
QQ 3285589261
Email
sales@twochem.com
Country
China
ProdList
1788
Advantage
58
WUHAN SUN-SHINE BIO-TECHNOLOGY Co., Ltd.
Tel
17702719238 18971495150;
Email
sales@sun-shinechem.com
Country
China
ProdList
1150
Advantage
64
Chembest Research Laboratories Limited
Tel
021-20908456
Fax
021-58180499
Email
sales@BioChemBest.com
Country
China
ProdList
6003
Advantage
61
Nanjing Chemlin Chemical Co., Ltd
Tel
025-83697070 13913916777
Fax
+86-25-83453306
Email
info@chemlin.com.cn
Country
China
ProdList
16029
Advantage
64
Shanghai Topbiochem Technology Co., Ltd
Tel
021-58170097 15801866362;
Email
info@topbiochem.com
Country
China
ProdList
9520
Advantage
58
Shanghai Jian Chao Chemical Technology Co., Ltd.
Tel
150-2103-5486 18017383231
Fax
qq：2817624287
Email
983544897@qq.com
Country
China
ProdList
9341
Advantage
55
ShangHai Caerulum Pharma Discovery Co., Ltd.
Tel
18149758185 18149758185
Email
sales-cpd@caerulumpharma.com
Country
China
ProdList
3505
Advantage
58
DKMbiochem.Co. Ltd
Tel
15901859516
Fax
15901859516
Email
sales@DKMbiochem.com
Country
China
ProdList
344
Advantage
58
Finetech Industry Limited
Tel
027-87465837 19945049750
Fax
027-8777-2287
Email
sales@finetechnology-ind.com
Country
China
ProdList
9548
Advantage
58

1693758-51-8, IPI-549Related Search:

S-Trityl-L-cysteine ZM 336372 LFM-A13 CL 82198 HYDROCHLORIDE

  • IPI-549
  • (S)-2-amino-N-(1-(8-((1-methyl-1H-pyrazol-4-yl)ethynyl)-1-oxo-2-phenyl-1,2-dihydroisoquinolin-3-yl)ethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
  • IPI-549(IPI549)
  • IPI-549, 98%, a potent and selective PI3Kγ Inhibitor
  • CS-2414
  • IPI-549; IPI 549; IPI549.
  • Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-amino-N-[(1S)-1-[1,2-dihydro-8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]-
  • IPI549 (Eganelisib)
  • Eganelisib
  • Eganelisib (IPI-549)
  • 2-Amino-N-[(1S)-1-[1,2-dihydro-8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
  • Eganelisib, 10 mM in DMSO
  • (S)-2-Amino-N-[1-[8-[(1-methyl-4-pyrazolyl)ethynyl]-1-oxo-2-phenyl-1,2-dihydro-3-isoquinolinyl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
  • Eganelisib (IPI-549) ，S8330
  • 2-Amino-N-[(1S)-1-[1,2-dihydro-8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-isoquinolin-3-yl]-ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
  • 1693758-51-8
  • API
  • APIs